oral glp-1 drugs in development GLP-1: how to win the next era The challenge of developing oral

This meta-analysis examined the connection between the injection of GLP-1 receptor agonists and the incidence of diverse respiratory diseases

Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits

[PubMed ID: 19065993]

Orforglipron does not directly displace these agents but rather complements them by offering an oral alternative for patients who prefer pills or do not require maximal weight loss

Neither GLP-1 (1-36amide) nor GLP-2, peptide fragments corresponding to the predicted structures from the gene sequence, were active on insulin secretion, but a truncated version of GLP-1 extractable from human and porcine gut was subsequently found to enhance insulin secretion in various experimental models [[80], [81], [82]] and, ultimately, in human studies, i.e